Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/187491INHIBITORS OF CYSTEINE PROTEASES
WO 09.09.2022
Int.Class A61K 38/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
Appl.No PCT/US2022/018714 Applicant THE TEXAS A& M UNIVERSITY SYSTEM Inventor MEEK, Thomas D.
Provided herein are pharmaceutical compositions including compounds having Formula (I) in an effective amount to inhibit cysteine protease as well as methods of using thereof.
2.WO/2022/061420FORMULATIONS COMPRISING BOTANICAL EXTRACTS
WO 31.03.2022
Int.Class A61K 31/365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
Appl.No PCT/AU2021/051126 Applicant APEX BIOTECH RESEARCH PTY LTD Inventor XIAO, Zhicheng
The invention relates generally to combinations and compositions comprising botanical extracts useful in the treatment or prevention of viral and bacterial infections. In particular, the invention relates to combinations and compositions comprising two or more compounds selected from andrographolide or a derivative, or pharmaceutically acceptable salt thereof, ursolic acid, or a pharmaceutically acceptable salt thereof, and piceid or a derivative, or pharmaceutically acceptable salt thereof and use of the combinations and compositions in the treatment or prevention of viral and bacterial infections.
3.WO/2022/027088LATERAL FLOW DEVICE AND USES THEREOF
WO 10.02.2022
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No PCT/AU2021/050839 Applicant THE UNIVERSITY OF MELBOURNE Inventor GODFREY, Dale
The present disclosure provides a lateral flow assay (LFA) device for detecting neutralising antibodies against SARS-CoV-2 in a biological fluid sample, and uses thereof. The assay uses competition of the neutralising antibodies present in the sample with the ACE2-RBD on the test strip, leading to binding inhibition and decrease in signal intensity in the test region.
4.WO/2021/229591NOVEL USE OF NON-IONIC SURFACTANT FOR THE TREATMENT OF COVID–19
WO 18.11.2021
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/IN2020/050643 Applicant KRISHNAMACHARI, Ramu Inventor RITHVIK, K
The present invention relates to a novel use of non-ionic surfactants for the treatment of diseases caused by viruses. The present invention particularly relates to the use of non-ionic surfactants for the treatment of a disease known as COVID 19 caused by coronavirus SARS-CoV-2. The present invention further teaches the use of taste masking agents/excipients. The present invention is further believed to be related to cleansing the coronaviruses from buccal cavities, throat or within the body of a subject by not allowing the said virus to attach to any cells of mucosal layers or epithelial cells thus allowing them to pass out of the body or getting digested inside the body. For this reason the molecules or the composition used herein of the present invention is termed by the applicant as "INTERNAL SOAP".
5.WO/2021/254582EFFICACY OF (SOFOSBUVIR PLUS LEDIPASVIR) IN EGYPTIAN PATIENTS WITH COVID-19COMPARED TO STANDARD OF CARE TREATMENT.
WO 23.12.2021
Int.Class A61K 31/439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
Appl.No PCT/EG2020/000013 Applicant ALMAZA MILITARY FEVER HOSPITAL Inventor EL-GOHARY, Mohamed Abdel-Salam
The antivirals ledipasvir is particularly attractive as therapeutics to combat the new corona virus with minimal side effects, commonly fatigue and headache. The drugs (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes. The present study aimed to test and suggest possible inhibitors, DAA drugs, currently in the market stop the infection immediately. Sofosbuvir, ledipasvir can be used against the new strain of coronavirus that emerged with promising results.
6.WO/2021/175857COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS
WO 10.09.2021
Int.Class A61K 38/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides
Appl.No PCT/EP2021/055187 Applicant PHARMA MAR, S.A. Inventor AVILÉS MARÍN, Pablo
The present invention relates to the use of compounds in the treatment of inflammation, preferably inflammation associated with activation of Toll-like receptors. The invention also relates to the use of compounds to treat pathogen-induced inflammation.
7.WO/2021/211792TREATMENT OF CORONAVIRUS INFECTIONS WITH AURANOFIN
WO 21.10.2021
Int.Class A61K 31/7135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7135Compounds containing heavy metals
Appl.No PCT/US2021/027404 Applicant GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor KUMAR, Mukesh
The present disclosure provides methods for treating viral infections, in particular treating coronavirus infections in a subject with auranofin.
8.WO/2022/162012ANTIBODIES BROADLY TARGETING CORONAVIRUSES AND USES THEREOF
WO 04.08.2022
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/EP2022/051776 Applicant ETH ZURICH Inventor SALLUSTO, Federica
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the spike (S) protein of coronaviruses. The antibodies, and antigen binding fragments thereof, broadly target coronaviruses, including different alpha- and betacoronaviruses. The invention also relates to nucleic acids that encode, and to cells that express such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments in the treatment and diagnosis of coronavirus infection. Furthermore, a recombinant peptide, polypeptide or protein comprising the epitope, to which the antibodies bind to, is provided, which may be useful in vaccination.
9.WO/2021/255218A PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-VIRAL PROTONOPHORE AND A SERINE PROTEASE INHIBITOR
WO 23.12.2021
Int.Class A61K 31/609
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
60Salicylic acid; Derivatives thereof
609Amides, e.g. salicylamide
Appl.No PCT/EP2021/066543 Applicant CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN Inventor WITZENRATH, Martin
The invention relates to a pharmaceutical combination, comprising a therapeutically effective amount of an anti-viral protonophore, and a therapeutically effective amount of a serine protease inhibitor. In preferred embodiments the invention relates to a combination of niclosamide and camostat mesylate. The invention further relates to a pharmaceutical composition comprising the combination, and use of the combination or composition in a treatment and/or prevention of a viral infection in a subject and/or a medical condition associated with a viral infection. In preferred embodiments the invention relates to the treatment and/or prevention of a SARS-CoV virus, preferably SARS-CoV-2.
10.WO/2022/076611NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER
WO 14.04.2022
Int.Class A61K 31/4166
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4166having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
Appl.No PCT/US2021/053846 Applicant THE PENN STATE RESEARCH FOUNDATION Inventor MISRA, Sougat
Disclosed herein are compositions and methods for increasing the expression of human SLC7A11. The compositions include a combination of compounds that exhibit anti-proliferative activity against cancer cells. The compositions and methods can be used to treat a subject with cancer. Disclosed are also compositions and methods of treating a coronavirus infection, Zika virus, influenza virus infection, human immunodeficiency virus (HIV), or Rhinovirus.